CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 123 enrolled
Drug / intervention
Erlotinib +1 moredrug
Likely dose
Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01565538
NCT01565538Phase 2Completed
CompareCT.gov

A Randomized Phase II Trial of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced EGFR Wild-Type and EGFR FISH-Positive Lung Adenocarcinoma

Si-Yu Wang·interventional·Posted Mar 28, 2012·Updated Sep 15, 2014

In Brief

A Phase 2 clinical trial evaluating Erlotinib and Pemetrexed for Lung Cancer. Completed, enrolled 123 participants across 1 site.

Detailed Summary

Both pemetrexed and erlotinib are second-line treatment options for patients with advanced non-small cell lung cancer. It is controversial that whether it is necessary to detect epidermal growth factor receptor (EGFR) mutation status for the EGFR-targeted therapy after the failure of standard chemotherapy. The role of EGFR gene copy number as a predictive marker remains controversial. Therefore, we investigate the efficacy of erlotinib and pemetrexed as second-line therapy in treating in patients with EGFR wild-type and EGFR FISH-positive advanced lung adenocarcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 28, 2012
Enrollment StartDec 1, 2008
Primary CompletionMay 1, 2012
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 14.3 years ago

Interventions

Erlotinibdrug

150 mg Given orally

Pemetrexeddrug

500mg/m2 Given IV